Chronic restlessness with antipsychotics.

  title={Chronic restlessness with antipsychotics.},
  author={Irene M Bratti and John M. Kane and Stephen R. Marder},
  journal={The American journal of psychiatry},
  volume={164 11},
Mr. B is a 34-year-old man with a 13-year history of schizophrenia. His early treatment consisted of brief trials of first-generation antipsychotics, which he refused to take for any significant period of time. He was then started on risperidone at an average of 5 mg/day. Within a few months, he and his mother noticed that he had upper and lower extremity tremor and profound motor restlessness, especially of the legs. These symptoms worsened until Mr. B was taken off risperidone and started on… 

Tables from this paper

Amisulpride withdrawal akathisia responding to aripiprazole with propranolol in first-onset psychosis: a case report

This case suggests that changing the regimen to aripiprazole with propranolol may be a potential option for amisulpride withdrawal akathisia superimposed on pre-existing hyperprolactinemia and a slow tapering and careful monitoring are recommended when switching from amisULpride to other antipsychotic drugs.

Severe agitation in depression precipitated by dasatinib

We describe a case of a man with chronic myeloid leukaemia who achieved remission through dasatinib therapy after being unable to tolerate several tyrosine kinase inhibitor (TKI) regimens due to

Subcortical epilepsy?

Findings provide support for a broader model of akathisia and RLS, incorporating the thalamus and GABA/glutamate system, and another prospective study of RLS and sleep showed that zolpidem, which is known to reduce thalamic GABA, led to striking symptomatic improvement.

Extrapyramidal side effects in first-episode schizophrenia treated with flupenthixol decanoate

Flupenthixol decanoate is well tolerated in patients with FES and certain clinical features of schizophrenia may be related to EPSEs, and ethnicity is a socio-cultural construct, and hence the differential risk of EPSEs should be interpreted according to ethnicity.

A Brief Overview of Iatrogenic Akathisia

Although its pathophysiology is not well-established, a decrease in dopaminergic activity appears to be an important etiological factor and the most effective treatment of akathisia includes administration of either a beta-adrenergic antagonist or a serotonergic 5HT2 receptor antagonist.

Akathisia and second-generation antipsychotic drugs

Even though akathisia is less prevalent with SGAs than with the first-generation drugs, it remains clinically important and all clinicians should be conversant with its recognition and management.

The clinical challenges of akathisia

Some of the confusion surrounding akathisia, its relationship to other disorders, and differential diagnosis, are addressed, as well as treatment alternatives.

Akathisia #282.

Extrapyramidal symptoms (EPS) encompass several acute/reversible and chronic/irreversible side effects of psychoactive medications. They are believed to be caused by blockade of dopamine receptors

The Mechanism of Drug-induced Akathisia

A possible mechanism for drug-induced akathisia based on the differential functions of the core and shell portions of the nucleus accumbens is described based on contemporary concepts regarding the mechanisms of compulsion, impulsivity, and depression.

Clinical Predictors of Extrapyramidal Symptoms Associated With Aripiprazole Augmentation for the Treatment of Late-Life Depression in a Randomized Controlled Trial.

Akathisia is a common side effect of aripiprazole, but it is typically mild and responds to dose reduction, and patients with greater baseline depression may warrant closer monitoring for akath isia.



Tardive akathisia: An analysis of clinical features and response to open therapeutic trials

Tardive akathisia is a particularly disabling form of tardive dyskinesia, frequently persistent for years and often resistant to therapy.

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

In this relatively brief study, the apparently increased comparative risk of agranulocytosis requires that the use of clozapine be limited to selected treatment-resistant patients.

Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes.

Risperidone-treated patients appeared to feel subjectively better, as indicated by less anxiety and depression and fewer extrapyramidal side effects, when compared with patients given a low dose of haloperidol.

Managing Antipsychotic-Induced Acute and Chronic Akathisia

Based on the available literature, propranolol or other lipophilic β-blockers seem to be the most consistently effective treatment for acute akathisia and addition of benzodiazepines would appear to be a sensible next choice, especially if subjective distress persists.

Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schizophrenic patients?

The experience leads us to suggest a trial of clozapine in a subgroup of schizophrenic patients, who in addition to refractory psychoses have persistent disabling akathisia, but given the risk of agranulocytosis with clozAPine, it is suggested that the usual treatment strategies for akATHisia be tried before clozabine is initiated in the approved manner.

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.

A survey of drug-induced extrapyramidal reactions.

  • F. Ayd
  • Psychology, Medicine
  • 1961
Drug-induced striopallidal symptoms can be adequately treated with antiparkinsonian drugs and a close parallel was found between drug-induced and naturally occurring extrapyramidal reactions.

Akathisia variants and tardive dyskinesia.

The findings suggested a possible relationship between pseudoakathisia, orofacial and limb dyskinesia, and the severity of negative schizophrenic symptoms.

Clozapine versus typical antipsychotics a retro- and prospective study of extrapyramidal side effects

There was a significantly lower prevalence of tardive dyskinesia (TD) in clozapine treated patients than control patients, and patients treated had less neuroleptic-induced emotional indifference and depression, but more autonomic side effects than controls.

The prevalence of akathisia in patients receiving stable doses of clozapine.

The data support the low prevalence of akathisia in patients receiving stable doses of clozapine monotherapy and provide further support that clozAPine has an ameliorating effect on tardive dyskinesia associated with traditional neuroleptic drugs.